The Third Central Clinical College of Tianjin Medical University, Tianjin, China; Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin, China; Artificial Cell Engineering Technology Research Center, Tianjin, China; Tianjin Institute of Hepatobiliary Disease, Tianjin, China.
Tianjin Union Medical Center, Tianjin Medical University, Tianjin, China.
Turk J Gastroenterol. 2023 Apr;34(4):413-420. doi: 10.5152/tjg.2023.22296.
The systemic immune-inflammation index reflects the systematic inflammatory status, and the albumin-bilirubin grade reflects the liver function. In patients with hepatocellular carcinoma receiving transarterial chemoembolization, their combined clinical utility has not been fully explored. Herein, we purposed to determine the prognostic worthiness of systemic immune-inflammation index -albumin-bilirubin scores in patients receiving transarterial chemoembolization for unresectable hepatocellular carcinoma.
Patients who were treated with transarterial chemoembolization after being diagnosed with hepatocellular carcinoma between 2008 and 2016 were recruited for this research work. Systemic immune-inflammation index and albumin-bilirubin scores were determined prior to treatment. The clinico-pathological factors related to overall survival were determined via univariate along with multivariate analyses.
A total of 295 patients were retrospectively studied. Patients with systemic immune-inflammation index-albumin-bilirubin score of 2 had the worst outcomes, exhibiting a median overall survival of 11 months (95% CI, 8.44-13.56 months) in contrast with subjects in the systemic immune-inflammation index-albumin-bilirubin 1 group (median OS, 26 months; 95% CI, 21.25-30.75 months) and the systemic immune-inflammation index-albumin-bilirubin 0 class (median OS, 31 months; 95% CI, 12.76-49.24 months). The 1-, 3-, and 5-year rates of survival were 45.3%, 1.3%, and 0% for patients in the systemic immune-inflammation index-albumin-bilirubin 2 category; 76.4%, 35.0%, and 14.6% for those in the systemic immune-inflammation index-albumin-bilirubin 1 category; and 85.6%, 46.7%, and 35.0% for those in the systemic immune-inflammation index-albumin-bilirubin 0 category, respectively (P < .001).
The systemic immune-inflammation index-albumin-bilirubin score could be a simple indicator to estimate the prognosis in individuals with hepatocellular carcinoma being treated with transarterial chemoembolization. Patients in the systemic immuneinflammation index-albumin-bilirubin 2 category were more likely to be related to a shorter overall survival.
全身免疫炎症指数反映全身炎症状态，白蛋白-胆红素分级反映肝功能。在接受经动脉化疗栓塞术的肝细胞癌患者中，其联合临床应用尚未得到充分探讨。本研究旨在确定全身免疫炎症指数-白蛋白-胆红素评分在接受不可切除肝细胞癌经动脉化疗栓塞术患者中的预后价值。
本研究纳入了 2008 年至 2016 年间诊断为肝细胞癌并接受经动脉化疗栓塞术治疗的患者。治疗前测定全身免疫炎症指数和白蛋白-胆红素评分。通过单因素和多因素分析确定与总生存相关的临床病理因素。
共回顾性研究了 295 例患者。全身免疫炎症指数-白蛋白-胆红素评分 2 分的患者预后最差，中位总生存期为 11 个月（95%CI：8.44-13.56 个月），而全身免疫炎症指数-白蛋白-胆红素 1 分组患者的中位总生存期为 26 个月（95%CI：21.25-30.75 个月），全身免疫炎症指数-白蛋白-胆红素 0 级患者的中位总生存期为 31 个月（95%CI：12.76-49.24 个月）。全身免疫炎症指数-白蛋白-胆红素 2 分类患者的 1、3 和 5 年生存率分别为 45.3%、1.3%和 0%；全身免疫炎症指数-白蛋白-胆红素 1 分类患者分别为 76.4%、35.0%和 14.6%；全身免疫炎症指数-白蛋白-胆红素 0 分类患者分别为 85.6%、46.7%和 35.0%（P<0.001）。
全身免疫炎症指数-白蛋白-胆红素评分可作为评估经动脉化疗栓塞术治疗肝细胞癌患者预后的简单指标。全身免疫炎症指数-白蛋白-胆红素 2 分类患者总生存期更短。
